摘要
目的比较培美曲塞联合顺铂与吉西他滨联合顺铂治疗非小细胞肺癌(NSCLC)的临床效果。方法选择2015年10月—2016年12月治疗的120例NSCLC患者的临床资料进行回顾性研究。按照化疗药物不同分为观察组65例和对照组55例。观察组给予培美曲塞联合顺铂治疗,对照组给予吉西他滨联合顺铂治疗。观察两组近期疗效,以及血清抗原125(CA125)、癌胚抗原(CEA)、神经元特异性烯醇化酶(NSE)、白介素-27(IL-27)、转化生长因子-β1(TGF-β1)和基质金属蛋白酶-2(MMP-2)变化情况,并观察化疗药物毒副反应。结果两组化疗的总有效率和毒副作用发生情况比较差异均无统计学意义(P> 0. 05)。化疗后,两组TGF-β1、MMP-2、CA125、CEA和NSE水平均低于化疗前,且观察组均低于对照组(P <0. 05)。化疗后,两组IL-27水平高于化疗前,且观察组高于对照组(P <0. 05)。结论培美曲塞与吉西他滨分别联合顺铂治疗NSCLC的效果相似。但培美曲塞联合顺铂更能改善患者肿瘤标志物指标,且能够抑制肿瘤细胞增殖、促进细胞凋亡。
Objective To compare clinical efficacy between Pemetrexed and Gemcitabine combined with Cisplatin in treatment of patients with non-small cell lung cancer(NSCLC).Methods Clinical data of 120 patients with NSCLC during October 2015 and December 2016 was retrospectively analyzed,and the patients were divided into observation group(n=65)and control group(n=55)according to different chemotherapeutics.Observation group was treated with Pemetrexed combined with Cisplatin,while control group was given Gemcitabine combined with Cisplatin.Short-term efficacy,changes of serum cancer antigen 125(CA125),carcinoembryonic antigen(CEA),neuron-specific enolase(NSE),interleukin-27(IL-27),transforming growth factor-β1(TGF-β1)and matrix metalloproteinase-2(MMP-2)levels and toxic and side reaction of chemotherapeutics were observed in two groups.Results There were no significant differences in total effective rate and incidence rate of toxic and side-effects between two groups(P>0.05).After chemotherapy,levels of TGF-β1,MMP-2,CA125,CEA and NSE were significantly lower than those before chemotherapy in two groups,and the levels in observation group were significantly lower than those in control group(P<0.05).After chemotherapy,IL-27 levels were significantly higher than those before chemotherapy in two groups,and the level in observation group was significantly higher than that in control group(P<0.05).Conclusion Pemetrexed or Gemcitabine combined with Cisplatin in treatment of patients with NSCLC may achieve similar clinical efficacy.However,Pemetrexed combined with Cisplatin may improve tumor marker indexes preferably,inhibit tumor cell proliferation and promote apoptosis.
作者
薛英杰
贾靖
吴杨
邵董
赵美芝
薛英超
XUE Ying-jie;JIA Jing;WU Yang;SHAO Dong;ZHAO Mei-zhi;XUE Ying-chao(Department of Oncology,People's Hospital of Dingzhou,Dingzhou,Hebei 073000,China;;Department of Iconography,Anguo Hospital,Anguo,Hebei 071200,China;Department of Oncology,Traditional Chinese Hospital of Xinle,Xinle,Hebei 050700,China)
出处
《解放军医药杂志》
CAS
2018年第12期11-14,共4页
Medical & Pharmaceutical Journal of Chinese People’s Liberation Army
基金
河北省医学科学研究重点课题(20181773)
关键词
培美曲塞
吉西他滨
癌
非小细胞肺
治疗效果
Pemetrexed
Gemcitabine
Carcinoma,non-small-cell lung
Treatment effectiveness
